Ultragenyx Pharmaceutical (RARE) Cash & Equivalents Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -51.77% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 24.73% |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -28.55% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 13.33% |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -16.07% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 21.66% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.88% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 36.53% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | 26.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.83% |
| Dec 31, 2025 | 46.85% |
| Sep 30, 2025 | -19.74% |
| Jun 30, 2025 | 3.32% |
| Mar 31, 2025 | -6.22% |
| Dec 31, 2024 | -17.30% |
| Sep 30, 2024 | -8.64% |
| Jun 30, 2024 | 18.23% |
| Mar 31, 2024 | -33.62% |
| Dec 31, 2023 | -33.06% |
| Sep 30, 2023 | -28.37% |
| Jun 30, 2023 | -32.76% |
| Mar 31, 2023 | -33.99% |
| Dec 31, 2022 | -32.57% |
| Sep 30, 2022 | 47.29% |
| Jun 30, 2022 | 6.77% |
| Mar 31, 2022 | -17.04% |
| Dec 31, 2021 | 39.45% |
| Sep 30, 2021 | 33.54% |
| Jun 30, 2021 | 37.93% |
| Mar 31, 2021 | 19.18% |
| Dec 31, 2020 | 92.21% |
| Sep 30, 2020 | 48.42% |
| Jun 30, 2020 | 54.65% |
| Mar 31, 2020 | 23.19% |
| Dec 31, 2019 | 39.09% |
| Sep 30, 2019 | -4.85% |
| Jun 30, 2019 | 33.61% |
| Mar 31, 2019 | 56.21% |
| Dec 31, 2018 | 6.63% |
| Sep 30, 2018 | -20.75% |
| Jun 30, 2018 | 28.41% |
| Mar 31, 2018 | 8.39% |
| Dec 31, 2017 | 60.46% |
| Sep 30, 2017 | 4.20% |
| Jun 30, 2017 | 73.25% |
| Mar 31, 2017 | 42.22% |
| Dec 31, 2016 | 178.90% |
| Sep 30, 2016 | 186.52% |
| Jun 30, 2016 | 59.75% |
| Mar 31, 2016 | 2.98% |